Adaptive Biotech (ADPT) Stock
Fundamentals
Latest news
About Adaptive Biotech
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Chad M. Robins M.B.A. | Co-Founder, CEO & Chairman | 1975 |
| Ms. Julie Rubinstein | President & COO | 1972 |
| Mr. Kyle Piskel | VP, CFO & Principal Accounting Officer | 1984 |
| Ms. Susan Bobulsky | Chief Commercial Officer of MRD | 1981 |
| Mr. Christopher Carlson Ph.D. | Founder | — |
| Ms. Karina Calzadilla | VP of Investor Relations and FP&A | — |
| Ms. Clarice McCauley | Head of Legal, Corporate Secretary, VP & Chief Compliance Officer | — |
| Mr. Francis T. Lo | Chief People Officer | 1981 |
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine | 1974 |
| Ms. Mary Pat Lancelotta | Senior Vice President of MRD BioPharma | — |



